Shattuck Labs, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Shattuck Labs, Inc. (Nasdaq: STTK) on March 4, 2024, covering events that occurred on March 1, 2024. The filing reports on corporate governance changes specifically regarding the expansion of the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The Board of Directors expanded its size and appointed two new directors effective immediately:
- Dr. Kate Sasser: Appointed as a Class II director, serving until the 2025 Annual Meeting. She previously served as Chief Scientific Officer at Tempus AI and held leadership roles at Genmab and Johnson & Johnson.
- Dr. Clay Siegall: Appointed as a Class III director, serving until the 2026 Annual Meeting. He is currently the CEO and Chairman of Immunome, Inc., and previously co-founded and led Seagen Inc. until its acquisition by Pfizer.
Neither director has been assigned to specific Board committees at this time.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on business outlook, or new risk factors. The appointments are subject to the Company's standard non-employee director compensation policy and indemnification agreements. No unusual items or contingencies were disclosed.
Key Facts for Investor Verification
- Verify the specific terms of the non-employee director compensation policy referenced in the 2023 Form 10-K.
- Confirm the future committee assignments for Dr. Sasser and Dr. Siegall, as none were designated in this filing.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for these appointments.